215 related articles for article (PubMed ID: 1352440)
1. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
2. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
4. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
5. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
6. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of sex steroid receptors in breast cancer using routine paraffin sections: comparison with frozen sections and enzyme immunoassay.
Elias JM; Margiotta M; Sexton TR; Heimann A
J Cell Biochem Suppl; 1994; 19():126-33. PubMed ID: 7823584
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
Hurlimann J; Gebhard S; Gomez F
Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
[TBL] [Abstract][Full Text] [Related]
9. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
11. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
Abadjian G; Antoun R
J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
13. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
[TBL] [Abstract][Full Text] [Related]
14. Biochemical parameters for prognostic evaluation in patients with breast cancer.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
[TBL] [Abstract][Full Text] [Related]
15. Automated and quantitative immunocytochemical assays of Bcl-2 protein in breast carcinomas.
Charpin C; Garcia S; Bouvier C; Devictor B; Andrac L; Lavaut MN; Allasia C
Br J Cancer; 1997; 76(3):340-6. PubMed ID: 9252201
[TBL] [Abstract][Full Text] [Related]
16. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
Chu JS; Lee WJ; Chen KM; Hsu HC
J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
[TBL] [Abstract][Full Text] [Related]
19. p53 quantitative immunocytochemical analysis in breast carcinomas.
Charpin C; DeVictor B; Andrac L; Amabile J; Bergeret D; LaVaut MN; Allasia C; Piana L
Hum Pathol; 1995 Feb; 26(2):159-66. PubMed ID: 7860046
[TBL] [Abstract][Full Text] [Related]
20. [Infiltrating ductal carcinomas of the breast in women over 60 years of age. Association with higher cellular proliferation and lower PS2, cell surface and cytosolic hyaluronic acid concentrations].
Ruibal A; Arias J; Del Río MC; Resino C; Tejerina A
Rev Esp Med Nucl; 2001 Dec; 20(7):525-9. PubMed ID: 11709137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
